Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The STARMEN trial postulated that in primary membranous nephropathy (pMN) treatment with tacrolimus plus rituximab would be superior to a traditional Ponticelli regimen of alternating cyclophosphamide and glucocorticoids. This was not the case. Significantly more remissions were achieved in cyclophosphamide-treated patients, and more of these were complete remissions. Considering these results with those of the Mentor trial, which compared rituximab with cyclosporine in pMN, we offer an evidence-based perspective on the role of calcineurin inhibition for pMN treatment. Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Citation

Jürgen Floege, Brad H Rovin. The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy. Kidney international. 2021 Apr;99(4):811-813

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33745547

View Full Text